KalVista Pharmaceuticals Newsroom

BofA Securities Initiates KalVista Pharmaceuticals(KALV.US) With Buy Rating, Announces Target Price $22

Futu NewsDec 18 20:34

B of A Securities Initiates Coverage On KalVista Pharma With Buy Rating, Announces Price Target of $22

BenzingaDec 18 20:14

Optimistic Buy Rating for KalVista Pharmaceuticals: Strategic Financial Moves and Promising Drug Launch Bolster Market Potential

TipRanksDec 10 14:09

KalVista Pharma Analyst Ratings

BenzingaDec 9 22:56

JonesTrading Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Cuts Target Price to $33

Futu NewsDec 7 01:31

H.C. Wainwright Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Maintains Target Price $20

Futu NewsDec 6 19:31

KalVista Pharmaceuticals Price Target Maintained With a $20.00/Share by HC Wainwright & Co.

Dow JonesDec 6 19:22

Analysts Conflicted on These Healthcare Names: Solid Biosciences (SLDB), Foghorn Therapeutics (FHTX) and KalVista Pharmaceuticals (KALV)

TipRanksDec 6 02:33

Needham Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Maintains Target Price $28

Futu NewsDec 6 02:31

KalVista Pharma Analyst Ratings

BenzingaDec 6 01:26

Needham Reiterates Buy on KalVista Pharma, Maintains $28 Price Target

BenzingaDec 6 01:24

Needham Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Cuts Target Price to $28

Futu NewsNov 5 06:31

KalVista Pharmaceuticals: Strategic Financing and Market Potential Drive Buy Rating

TipRanksNov 5 05:36

KalVista Pharma Analyst Ratings

BenzingaOct 7 18:59

H.C. Wainwright Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Maintains Target Price $20

Futu NewsOct 7 18:31

KalVista Pharmaceuticals Initiated at Buy by Jones Trading

Dow JonesSep 27 21:49

KalVista Pharma Analyst Ratings

BenzingaSep 27 21:39

JonesTrading Initiates KalVista Pharmaceuticals(KALV.US) With Buy Rating, Announces Target Price $35

Futu NewsSep 27 19:31

Buy Rating Affirmed for KalVista Pharmaceuticals Amid Strong Phase 3 Data and Market Potential

TipRanksSep 27 19:27

Leerink Partners Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Maintains Target Price $20

Futu NewsSep 7 00:31